Skip to main content
OpenTrials
Completed

NCT Number: NCT02090387

Evaluation of an Oral Nutritional Supplement on Lean Body Mass in Healthy Older Subjects.

The study will evaluate the effects of oral nutritional supplements (ONS) on attenuating the lean body mass (LBM) loss that occurs after bed rest.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

60 year–79 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 60 to ≤ 79 years
  • Body Mass Index (BMI) >20 but ≤ 35 kg/m2.
  • Short Physical Performance Battery (SPPB) score of > 9 (fully functional with no mobility limitations).
  • Triacylglyceride (TAG) level is ≤ 250 mg/dl, LDL cholesterol is ≤ 155 mg/dl, total cholesterol level is ≤ 250 mg/dl.
  • Compliance with the various activity levels required for this study.
  • Ankle brachial index within the normal range, between 1 and 1.4.
  • Physical activity score within the 2008 Guidelines for Americans.
  • Normal-good handgrip strength.

Exclusion criteria

  • Type I or Type II Diabetes Mellitus.
  • Fasting blood glucose level of >115 mg/dl.
  • Major surgery, less than 6 weeks prior to enrollment in the study, or subject has planned elective surgery requiring 2 or more days of hospitalization.
  • History of pressure ulcers.
  • Stated history of Deep Vein Thrombosis (DVT), recent elevated D-dimer test, a positive ultrasound for DVT, pulmonary embolism, carotid atherosclerosis, transient ischemic attack (TIA), or stated hypercoaguable condition, or other clotting or bleeding disorders, or is currently prescribed blood thinners.
  • Varicose veins that would result in significant discomfort while wearing TED hose and/or SCD.
  • Stated autoimmune disease or active malignant disease.
  • Estimated glomerular filtration rate is < 50ml/min/1.73m2.
  • Current significantly impaired liver function or hepatic enzyme tests are ≥2.5 times normal limit.
  • Significant cardiovascular event ≤ 6 months prior to screening visit; or stated history of congestive heart failure.
  • Untreated hypo- or hyper-thyroidism, or other endocrinopathies associated with excessive androgen secretion.
  • Refractory anemia with hemoglobin value <11.0 g/dl.
  • Chronic, contagious, infectious disease, such as active tuberculosis, hepatitis B or C, or HIV.
  • Current infection (requiring prescription antimicrobial or antiviral medication, or hospitalization), or has received corticosteroid treatment (with the exception of inhaled or topical steroids) in the last 3 months.
  • Currently being prescribed pain/anti-inflammatory medication and/or is regularly consuming over the counter pain/anti-inflammatory medication for chronic, or persistent, pain, including but not limited to arthritic conditions, fibromyalgia, and continuous localized pain.
  • History of allergy to any of the ingredients in the study products.
  • Deleted
  • Obstruction of the gastrointestinal tract precluding ingestion of the study product, inflammatory bowel disease, short bowel syndrome or other severe forms of gastrointestinal disease.
  • Stated uncontrolled severe diarrhea, nausea or vomiting.
  • Amputee.
  • Actively pursuing weight loss or gain.
  • Cannot refrain from taking medications/dietary supplements (all forms)/substances that could modulate metabolism or body weight.
  • Cannot refrain from taking long chain n-3 polyunsaturated fatty acids (PUFA) (eicosapentaenoic acid (EPA) ± docosahexaenoic acid (DHA) ± α-linolenic acid (ALA)), or vitamin D, at levels that are significantly higher than the established Acceptable Macronutrient Distribution Range (AMDR), or recommended by the American Heart Association (500 mg/d total EPA+DHA), during the study.
  • Cannot refrain from smoking or discontinue the use of nicotine (all forms including patches) or tobacco during the study.
  • One or more metal implants.
  • Currently diagnosis or a history of severe dementia or delirium, eating disorder, history of significant neurological or psychiatric disorder, alcoholism, substance abuse or other conditions that may interfere with study product consumption or compliance.
  • Cannot abstain from alcohol use during the study.

Treatment and study plan

ONS without AN777

Other

2 servings a day

Other names: Commercially available ONS

ONS containing AN777

Other

2 servings a day

Other names: Investigational ONS

Primary outcomes

  1. Total lean body mass

    Time frame: Baseline to Study Day 10

    Change from baseline

Secondary outcomes

  1. Hand-grip strength

    Time frame: Baseline, Study Day 10, Study Week 6 and 12

    Change from baseline

  2. Short Physical Performance Battery (SPPB)

    Time frame: Baseline, Study Day 10, Study Week 6 and 12

    Change from baseline

  3. Isokinetic leg strength

    Time frame: Baseline, Study Day 10 and Study Week 12

    Change from baseline

  4. Body Mass Index (BMI)

    Time frame: Screening Visits 1 and 3; Baseline; Study Days 2, 4, 6, 8 and 10; Study Weeks 3, 6, 9 and 12

    Calculated BMI = weight/height2 (kg/m2).

  5. Lower extremity lean mass

    Time frame: Baseline, Study Day 10, Study Weeks 6 and 12

    Measured by DXA; Change from baseline

Sponsors and collaborators

Lead sponsor

Abbott Nutrition

Industry

Registry information

Official study title

Evaluation of a Complete Oral Nutritional Supplement on Lean Body Mass in Healthy Older Subjects During Bed Rest and Recovery.

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
Mar 18, 2014
Registry last updated
Jul 11, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.